Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (TOI) FCF Margin (2021 - 2025)

Oncology Institute's FCF Margin history spans 5 years, with the latest figure at 1.53% for Q4 2025.

  • For Q4 2025, FCF Margin fell 71.0% year-over-year to 1.53%; the TTM value through Dec 2025 reached 5.53%, up 223.0%, while the annual FY2025 figure was 5.53%, 218.0% up from the prior year.
  • FCF Margin reached 1.53% in Q4 2025 per TOI's latest filing, up from 9.69% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 2.24% in Q4 2024 to a low of 46.28% in Q4 2021.
  • Average FCF Margin over 5 years is 14.1%, with a median of 11.61% recorded in 2023.
  • The largest YoY upside for FCF Margin was 2389bps in 2022 against a maximum downside of -3228bps in 2022.
  • A 5-year view of FCF Margin shows it stood at 46.28% in 2021, then soared by 52bps to 22.39% in 2022, then skyrocketed by 75bps to 5.54% in 2023, then soared by 140bps to 2.24% in 2024, then crashed by -32bps to 1.53% in 2025.
  • Per Business Quant, the three most recent readings for TOI's FCF Margin are 1.53% (Q4 2025), 9.69% (Q3 2025), and 9.52% (Q2 2025).